EMPLOYMENT AGREEMENTEmployment Agreement • March 30th, 2017 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • Massachusetts
This Employment Agreement (the “Agreement”) is made and entered into by and between Claude Knopf (“Executive”) and Pieris Pharmaceuticals, Inc., a Nevada corporation (the “Company”) (together referred to herein as the “Parties”), effective as of November 11, 2016 (the “Effective Date”).
LICENSE AND COLLABORATION AGREEMENT BETWEEN LES LABORATOIRES SERVIER INSTITUT DE RECHERCHES INTERNATIONALES SERVIER AND PIERIS PHARMACEUTICALS, INC. PIERIS PHARMACEUTICALS GMBH Portions of the exhibit, indicated by the mark “[***],” were omitted and...License and Collaboration Agreement • March 30th, 2017 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
This License and Collaboration Agreement is entered into as of January 4, 2017 (the “Effective Date”) by and between Les Laboratoires Servier, a corporation incorporated under the laws of France having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France and Institut de Recherches Internationales Servier, a company duly organized and existing under the laws of France having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France (individually and collectively, “Servier”), and Pieris Pharmaceuticals, Inc., a Nevada corporation having offices and principal place of business at 255 State Street, 9th floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a company organized and existing under the laws of Germany having offices and principal place of business at Lise-Meitner-str. 30, 85354 Freising, Germany (individually and collectively, “Pieris”). Servier and Pieris are individually referred to herein as a “Party” and coll
NON-EXCLUSIVE ANTICALIN® PLATFORM TECHNOLOGY LICENSE AGREEMENTTechnology License Agreement • March 30th, 2017 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
THIS NON-EXCLUSIVE ANTICALIN® PLATFORM TECHNOLOGY LICENSE AGREEMENT (“Agreement”) is made and entered into effective as of January 4, 2017 (the “Effective Date”), by and between PIERIS PHARMACEUTICALS, INC., a Nevada corporation having its principal place of business at 255 State Street, 9th floor, Boston, MA 02109 AND PIERIS PHARMACEUTICALS GMBH, a company organized and existing under the laws of Germany having offices and principal place of business at Lise-Meitner-str. 30, 85354 Freising, Germany (collectively, “Pieris”), and LES LABORATOIRES SERVIER, a corporation incorporated under the laws of France having a principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France and INSTITUT DE RECHERCHES INTERNATIONALES SERVIER, a company duly organized and existing under the laws of France, having offices and principal place of business at 50 Rue Carnot, 92284 Suresnes Cedex, France (collectively, “Licensee”). Pieris and Licensee each may be referred to herein individually a
CONSULTING AGREEMENTConsulting Agreement • March 30th, 2017 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • Massachusetts
This Consulting Agreement (the “Agreement”) is entered into on February 1, 2017, by and between Pieris Pharmaceuticals, Inc., a Nevada corporation, with its principal place of business being Lise-Meitner-Strasse 30, 85354 Freising-Weihenstephan, Germany (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principal place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”). The Company and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.”
February 7, 2017Separation Agreement • March 30th, 2017 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research • Massachusetts
The purpose of this letter agreement (the “Agreement”) is to set forth the terms of your separation from Pieris Pharmaceuticals, Inc. (“Pieris” or the “Company”). Payment of the Separation Benefit described below is contingent on your agreement to and compliance with the terms of this Agreement. This Agreement shall become effective on the date that is the eighth (8th) day following your execution of it, as explained more fully in Section 6 below (the “Effective Date”).
AMENDMENT NO. 1 TO DEFINITIVE LICENSE AND TRANSFER AGREEMENTDefinitive License and Transfer Agreement • March 30th, 2017 • Pieris Pharmaceuticals, Inc. • Services-commercial physical & biological research
This Amendment No. 1 to Definitive License and Transfer Agreement (this “Amendment”), effective as of January 3, 2017 (the “Amendment Effective Date”), is by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation with a place of business at 200 Cambridge Park Drive, Suite 2000, Cambridge, MA 02140 (“Enumeral”) and Pieris Pharmaceuticals, Inc., a Nevada corporation with a place of business at 255 State Street, 9th Floor, Boston, MA 02109 and Pieris Pharmaceuticals GmbH, a German company with a place of business at Lise-Meitner-Strasse 30, 85354 Freising, Germany (collectively, and together with their Affiliates, “Pieris”), under which the Parties mutually agree to modify and amend the Definitive License and Transfer Agreement between the Parties, with an Effective Date of June 6, 2016 (the “Agreement”), as set forth below. Capitalized terms used in the Amendment but not defined herein shall have the meanings set forth in the Agreement.
